• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Thyroid cancer: Balancing benefit and risk in TSH management of DTC.

作者信息

Verburg Frederik A, Luster Markus

机构信息

University Hospital Marburg, Department of Nuclear Medicine, Marburg, Germany.

出版信息

Nat Rev Endocrinol. 2018 Mar;14(3):136-137. doi: 10.1038/nrendo.2018.1. Epub 2018 Jan 19.

DOI:10.1038/nrendo.2018.1
PMID:29348477
Abstract
摘要

相似文献

1
Thyroid cancer: Balancing benefit and risk in TSH management of DTC.甲状腺癌：分化型甲状腺癌促甲状腺激素管理中获益与风险的平衡
Nat Rev Endocrinol. 2018 Mar;14(3):136-137. doi: 10.1038/nrendo.2018.1. Epub 2018 Jan 19.
2
Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study.分化型甲状腺癌患者的长期心血管死亡率：一项观察性研究。
J Clin Oncol. 2013 Nov 10;31(32):4046-53. doi: 10.1200/JCO.2013.49.1043. Epub 2013 Oct 7.
3
Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.分化型甲状腺癌中促甲状腺激素抑制治疗的获益与不良反应风险。
Thyroid. 2010 Feb;20(2):135-46. doi: 10.1089/thy.2009.0311.
4
Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.分化型甲状腺癌中促甲状腺激素抑制性左甲状腺素治疗的风险效益比。
Ann Endocrinol (Paris). 2015 Feb;76(1 Suppl 1):1S47-52. doi: 10.1016/S0003-4266(16)30014-2.
5
Is the incidence of differentiated thyroid cancer increased in patients with thyrotropin-secreting adenomas? Report of three cases from a large consecutive series.促甲状腺素分泌腺瘤患者中分化型甲状腺癌的发病率是否增加？来自一个大型连续病例系列的三例报告。
Thyroid. 2015 Apr;25(4):417-24. doi: 10.1089/thy.2014.0222. Epub 2015 Mar 9.
6
Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study.促甲状腺激素抑制疗法治疗低危小甲状腺癌：一项倾向评分匹配队列研究。
Thyroid. 2017 Sep;27(9):1164-1170. doi: 10.1089/thy.2017.0177. Epub 2017 Aug 8.
7
Recombinant Human Thyrotropin Improves Endothelial Coronary Flow Reserve in Thyroidectomized Patients with Differentiated Thyroid Cancer.重组人促甲状腺素可改善甲状腺切除术后分化型甲状腺癌患者的冠状动脉血流储备。
Thyroid. 2016 Nov;26(11):1528-1534. doi: 10.1089/thy.2016.0082. Epub 2016 Oct 14.
8
Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.血清促甲状腺激素水平为30 μIU/mL时，术前甲状腺球蛋白不足以作为分化型甲状腺癌的预后标志物。
Endocrine. 2016 Jul;53(1):166-73. doi: 10.1007/s12020-015-0842-0. Epub 2016 Jan 18.
9
Preoperative TSH level and risk of thyroid cancer in patients with nodular thyroid disease: nodule size contribution.结节性甲状腺疾病患者术前促甲状腺激素水平与甲状腺癌风险：结节大小的影响
Endocrinol Nutr. 2015 Jan;62(1):24-8. doi: 10.1016/j.endonu.2014.06.002. Epub 2014 Jul 25.
10
Higher TSH level is a risk factor for differentiated thyroid cancer.较高的促甲状腺激素（TSH）水平是分化型甲状腺癌的一个风险因素。
Clin Endocrinol (Oxf). 2013 Mar;78(3):472-7. doi: 10.1111/cen.12027.

引用本文的文献

1
An 8 miRNA-Based Risk Score System for Predicting the Prognosis of Patients With Papillary Thyroid Cancer.一个基于 8 个 miRNA 的风险评分系统，用于预测甲状腺乳头状癌患者的预后。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820965594. doi: 10.1177/1533033820965594.

本文引用的文献

1
Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer.分化型甲状腺癌患者的长期心血管发病率和死亡率。
Clin Endocrinol (Oxf). 2018 Feb;88(2):303-310. doi: 10.1111/cen.13519. Epub 2017 Dec 14.
2
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南：美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
3
Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.
分化型甲状腺癌治疗后的长期结局：1987 - 2012年NTCTCS登记分析
J Clin Endocrinol Metab. 2015 Sep;100(9):3270-9. doi: 10.1210/JC.2015-1346. Epub 2015 Jul 14.
4
The thyroid axis 'setpoints' are significantly altered after long-term suppressive LT4 therapy.长期抑制性左甲状腺素（LT4）治疗后，甲状腺轴的“设定点”会发生显著改变。
Horm Metab Res. 2014 Oct;46(11):794-9. doi: 10.1055/s-0034-1375678. Epub 2014 May 27.
5
The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study.甲状腺疾病谱与新发心房颤动风险：一项大型人群队列研究。
BMJ. 2012 Nov 27;345:e7895. doi: 10.1136/bmj.e7895.
6
Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients.分化型甲状腺癌患者的预期寿命在诊断时存在广泛局部肿瘤侵犯、侧方淋巴结或远处转移（≥45 岁），以及所有其他 DTC 患者正常的情况下会降低。
J Clin Endocrinol Metab. 2013 Jan;98(1):172-80. doi: 10.1210/jc.2012-2458. Epub 2012 Nov 12.
7
Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma.中强度 vs 严格 TSH 抑制对晚期分化型甲状腺癌生存的影响。
Clin Endocrinol (Oxf). 2012 Apr;76(4):586-92. doi: 10.1111/j.1365-2265.2011.04272.x.
8
Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.长期 TSH 抑制性左甲状腺素治疗后甲状腺轴的变化。
Clin Endocrinol (Oxf). 2012 Apr;76(4):577-81. doi: 10.1111/j.1365-2265.2011.04262.x.
9
Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma.外源性亚临床甲状腺功能亢进症和短期显性甲状腺功能减退症都会影响分化型甲状腺癌患者的心肌应变。
Thyroid. 2011 May;21(5):471-6. doi: 10.1089/thy.2010.0319. Epub 2011 Mar 21.
10
Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer.分化型甲状腺癌患者血清促甲状腺激素浓度与复发及死亡的相关性
J Clin Endocrinol Metab. 2007 Jul;92(7):2610-5. doi: 10.1210/jc.2006-2566. Epub 2007 Apr 10.